International Cancer Cluster Showcase 2017

Monday, June 19, 2017; 11:30 a.m. – 4:30 p.m.
San Diego Convention Center, Rooms 26AB and 27AB

Kindly sponsored by:

11:30 – 12:30 p.m.	**REGISTRATION AND LIGHT LUNCH with POSTER SESSION**
12:30 – 12:45 p.m.	**Opening and Welcome by ICCS Organizing Partners and Sponsors** Welcome Notes by Allison Hilton, Senior Advisor, Healthcare Corporate Banking, DNB Healthcare and by Andrea Cotton, Head of Strategic Development, EU and APAC, Precision for Oncology
12:45 – 1:00 p.m.	**Québec, Canada** Oncopole / IRICoR QCroc Feldan Therapeutics
1:00 – 1:15 p.m.	**Oslo Cancer Cluster, Norway** Inven2 Oncoimmunity NordicNanovector
1:15 – 1:30 p.m.	**Massachusetts Technology Transfer Center, USA** AcuityBio Cellanyx Cyteir Therapeutics
1:30 – 1:45 p.m.	**OBN, United Kingdom** Crescendo Biologics Oxstem Sareum
1:45 – 2:15 p.m.	**NETWORKING BREAK & POSTER SESSION**
2:15 – 2:25 p.m.	**Takeda Oncology Presentation,** Paul E. Juniewicz, Senior Director, Oncology Search & Evaluation, Center for External Innovation
2:25 – 2:35 p.m.	**NCI SBIR Development Center,** Todd Haim, SBIR Program Director at National Cancer Institute
2:35 – 2:50 p.m.	**Wistar Institute and Partners, Philadelphia, USA** ISOMA Diagnostics PepVax, Inc. NearUS: EU funded project to boost EU-US R&I collaboration, Blandine Chantepie-Kari, EAEC
2:50 – 3:05 p.m.	**Stanford SPARK, USA** Wong Laboratory: Peptide vaccine to treat Glioblastoma SPARK Portfolio: Update on novel oncology opportunities
3:05 – 3:30 p.m.	**Medicen Paris Region, France & BioCat / Catalonia Trade & Investment** OSE Immunotherapeutics, France Ariana Pharma, France FlashCell, France Ability Pharmaceuticals, Catalonia Zeclinics, Catalonia
3:30 – 3:35 p.m.	**Poster Partner BioWin, Belgium:** PDC*Line Pharma
3:35 – 4:30 p.m.	**NETWORKING RECEPTION & POSTER SESSION** www.internationalcancercluster.org

Presenting companies International Cancer Cluster Showcase 2017

Ability Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of a new drug class for cancer treatment. The first candidate, ABTL0812, stimulates the overexpression of TRIB3, an endogenous inhibitor of Akt, thus blocking the PI3K/Akt/mTOR pathway and causing the cell death by autophagy (Published in Clinical Cancer Research, May 2016). ABTL0812 completed the first in humans phase I/Ib clinical trial with the best safety and tolerability in the drug class and efficacy comparable to other PI3K/Akt/mTOR pathway inhibitors (several long-term disease stabilizations lasting up to 18 months). Phase 2 clinical trials started in September 2016 in lung and endometrial cancer (80 patients) in Spain and France. An ODD was granted by the EMA and FDA for neuroblastoma and by the FDA for pancreatic cancer. –
Contact: Carles Domenech, CEO; T: +34 606433824; carles.domenech@abilitypharma.com; www.abilitypharma.com

AcuityBio: Lung cancer recurrence kills approximately half of all lung cancer patients treated with surgery. AcuityBio's has produced a proprietary drug-eluting polymer platform technology, "ABC103." This product has been designed to be secured to the resection margin at the time of standard of care lung cancer resection surgery, delivering approved efficacious drugs, thereby preventing recurrence. Extensive large animal preclinical data has demonstrated that ABC103 safely sustains therapeutic levels of paclitaxel for greater than 60 days in all tissues with the highest risk for recurrence (i.e. lymphatics, ipsilateral lung chest wall and brain). ABC103 has been granted Orphan Drug status by FDA OOPD. FDA pre-IND written response confirmed that ABC103 will be reviewed by FDA under 505(b)(2). FDA further defined and validated AcuityBio's plan for rapid approval for ABC103 monotherapy, requiring only single Phase I and single Phase III clinical trials. Emerging evidence indicates that one of the mechanisms of actions of chemotherapy is via activation of the immune system through multiple pathways. Therefore, co-administration of the low toxicity ABC103 with immuno-oncology drugs is currently being explored.
Contact: John "Jay" Schwartz, CEO – Chairman; jschwartz@acuitybio.com; www.acuitybio.com

Ariana® is a leading digital health company focused on developing advanced personalized therapeutic decision support systems. Ariana® has developed the most advanced oncology treatment selection system **Onco KEM®**. Going beyond DNA and including RNA expression data, Onco KEM® helps cancer specialists choose optimal therapeutics for each patient, providing a personalized ranking of existing treatments. Onco KEM® has been validated in the first international clinical trial WINTHER in major cancer centers around the world (Gustave Roussy, France, MD Anderson and UCSD, USA, Sheim Sheba, Israel, Val d'Hebron, Spain and McGill, Canada). The trial first results have been published in March 2017: Onco KEM® enables precision medicine for all patients, including 36% of patients that would have no choice with existing DNA based tests. Onco KEM® has demonstrated efficacy, improving outcomes, as well as decreasing treatment costs. It is accessible via a web-based portal with patient specific reports for proposed treatments.
Contact: Mohammad AFSHAR, CEO; T: +33 6 79 61 03 22; m.afshar@arianapharma.com; www.arianapharma.com

Cellanyx is developing a proprietary living cell phenotypic cancer patient stratification platform to aid clinical decision making in cancer patients. The company's unique 'biopsy-on-a-chip' provides quantitative and actionable, predictive clinical scores of tumor aggressiveness, metastatic potential and adverse pathology based on multiple dynamic and static phenotypic biomarkers from live tumors with single-cell resolution. Cellanyx has demonstrated clinical validation in its lead indication in prostate cancer to accelerate precision drug development and patient risk stratification for prostate cancer.
Contact: Ashok C. Chander, CEO; T: +1571.212.9991; ashok@cellanyx.com; www.cellanyx.com

Crescendo Biologics, Cambridge, UK, is a biopharmaceutical company that is using its patent-protected transgenic mouse platform to discover and develop potent, highly differentiated Humabody® therapeutics with a focus on oncology. Humabody® therapeutics are based on 100% human V_H domain building blocks that offer a unique combination of potential benefits: they are very small (12 kDa per building block), potent and robust allowing Crescendo to rapidly assemble and optimally configure an almost limitless range of bespoke formats. Crescendo is pursuing novel product opportunities, through both in-house development and strategic partnerships, in both multifunctional immuno-oncology modulators (optimally configured for targeting a range of key synergistic mechanisms) and HDCs (Humabody® Drug Conjugates) the next generation of ADCs capable of delivering a superior therapeutic index.
Contact: Peter Pack, CEO; pack@crescendobiologics.com; www.crescendobiologics.com

Cyteir Therapeutics is a leader in the discovery and development of novel therapeutics based on the biology of DNA repair and synthetic lethality for the treatment of cancer and autoimmune diseases. Our initial approach takes advantage of the gain in function from DNA damage overload to induce selective self-destruction of cells by targeting disease-induce RAD51 transport. Our lead molecules were initially discovered using our drug discovery platform using primary cells which contain tunable genetic constraints. The Company is optimizing its lead RAD51 compounds in order to identify a clinical candidate for cancers and has a wealth of efficacy, safety and mechanistic data around its lead compounds. In addition, the Company believes it has demonstrated the first synthetic lethal approach to treating pathogenic B cell driven autoimmune diseases which was recently reported in The Journal of Immunology. Celgene Corporation is an investor in the Company and we are in the process of raising a Series B financing.
Contact: Don Corcoran, President and CEO; donald.corcoran@cyteir.com; www.cyteir.com

Feldan Therapeutics has developed a protein-based platform for direct delivery of proteins inside cells called the Feldan Shuttle. The company also possesses a recombinant protein production unit with an expertise in the manufacture of high-quality therapeutic proteins, such as nucleases and transcription factors. This fully integrated structure has led to a business model focused on the in-house development of gene-modified cell therapies and the co-development of other applications with corporate and academic partners. These distinct characteristics coupled with a deep scientific knowledge will allow Feldan to become the prime developer of gene modified cell therapies in Canada.
Contact: François Thomas Michaud, CEO; T: +1 418 872 7277, 337; ftmichaud@feldan.com; www.feldan.com

FlashCell, a spin-off of Vectalys, is a new fully integrated gene therapy company proposing its proprietary LentiFlash® new generation of non-integrative lentiviral vector for the development of RNA carriers in therapeutic applications, such as Gene-editing and Immunotherapy, in the fields of cancer, infectious diseases and genetic diseases. FlashCell is seeking for co-development and licensing partnership opportunities. **Contact:** Jean-Pierre Saintouil, Business Development Manager; T: +33 687618312; jean-pierre.saintouil@flashcell.fr; www.flashcell.fr

Inven2 is the technology transfer office and innovation company owned by the University of Oslo and Oslo University Hospital. Inven2 commercializes inventions from 6000 scientists at these institutions and the other health enterprises in South-East Norway. A growing number of Oncology Biotechs, including Nordic Nanovector, Ultimovacs, Vaccibody, Oncoinvent and Zelluna have been developed from the Inven2 portfolio. From its pipeline of new opportunities, Inven2 will present five projects in verification (pre-company) stage:

- Gene editing high precision kit
- CAR targeting CD37
- Immunotherapy targeting tumor stroma
- Novel prostate cancer biomarker
- BladMetrix – a urine test for early detection and monitoring of bladder cancer

Contact: Jonny Ostensen, VP Technology; T: +47 91192236; jonny.ostensen@inven2.com; www.inven2.com

Isoma Diagnostics is developing a molecular stratification system using the differential expression of key transcript variants (isoform-level gene expression) as a prognostic and diagnostic tool for glioblastoma (GBM). This technology holds promise as a robust diagnostic assay for patient stratification and prognosis assignment in a number of cancers. In addition to prognostic value, the transcript/isoform-based classifier has identified novel targets for pharmacotherapies and tailored treatments for GBM. Our novel classifier is platform-independent and has been validated in an independent cohort of 206 GBM samples with 92% accuracy.
Contact: Steven C. Davis, CEO; T: +1 (215) 219-9152; sdavis@isomadx.com; www.isomadx.com

Nordic Nanovector (www.nordicnanovector.com) is committed to develop and deliver innovative, targeted therapies to patients, to address major unmet medical needs and advance cancer care. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need. Betalutin® is targeting first regulatory submission for R/R follicular lymphoma in 1H 2019. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.
Contact: Marco Renoldi, COO; T: +41 788596989; mrenoldi@nordicnanovector.com; www.nordicnanovector.com

OncoImmunity is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bone fide immunogenic neoantigens for personalized cancer immunotherapy. One of the company's product offerings, the Immune-Profiler, is a machine-learning engine that predicts antigens that are processed and presented to the tumor cell surface and therefore potentially be immunogenic. OncoImmunity is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal targets for truly personalized cancer vaccines & cell therapies in a clinically actionable time-frame.
Contact: Richard Stratford, CEO; T: +47 900 15 242; richard@oncoimmunity.com; www.oncoimmunity.com

The Oncopole is a research, development, and investment hub to accelerate the fight against cancer located in Montreal. Founded in 2017 by Merck and the Fonds de recherche du Québec – Santé, the Oncopole invests strategically to maximize the full potential of Québec's cancer research and innovation ecosystem and ensure its growth, impact, and integration of practices and medicines. A unique structuring model built around the patient and bringing together partners from the government, private, academic, and entrepreneurship sectors, it aims at taking cancer care to the highest international standards.
Contact: Stéphanie Lord Fontaine, Executive Director; T: +1 514 343 7894; slord fontaine@oncopole.ca; www.oncopole.ca

OSE Immunotherapeutics is a biotechnology company focused on the development of innovative immunotherapies for immune activation and regulation in immuno-oncology, auto-immune diseases and transplantation. The company has a balanced portfolio of first-in-class products with a diversified risk profile ranging from clinical phase 3 registration trials to R&D:
In immuno-oncology: * Tedopi® (OSE-2101), combination of 10 optimized neo-epitopes to induce specific T activation in immuno-oncology - In registration Ph 3 in advanced NSCLC * OSE-172 (Effi-DEM), new generation checkpoint inhibitor targeting the SIRP-α receptor - In preclinical development for several cancer models
In auto-immune diseases and transplantation: * FR104, CD28-antagonist in immunotherapy – Ph 1 completed - For the treatment of autoimmune diseases and for use with transplantation - Licensed to Janssen Biotech Inc. to pursue clinical development * OSE-127 (Effi-7), interleukin receptor-7 antagonist - In preclinical development for inflammatory bowel diseases and other autoimmune diseases. License option agreement with Servier for its development and commercialization
Contact: Alexis PEYROLES, COO; T: +33 6 11 51 19 77 ; alexis.peyroles@ose-immuno.com; http://ose-immuno.com/en/

OxStem is a regenerative medicine drug-discovery company developing treatments for diseases with high unmet clinical need. Our mission is to transform healthcare for patient benefit. We will do this by providing revolutionary, viable new treatments that treat degenerative diseases and enable life-longevity. Most of the regenerative medicine field is developing stem cell transplantation therapies. OxStem however, is taking a different and novel approach. The human body already has the potential to repair and regenerate itself, stored within populations of resident stem and progenitor cells, but the repair mechanisms are switched off or rapidly slowed down after adult development. OxStem develops small molecule drugs that target these resident stem and progenitor cell populations and re-activates their existing repair mechanisms in situ. This completely avoids transplantation of cells and therefore circumvents the associated tolerance and rejection issues with cell therapies. OxStem currently has four subsidiary companies: OxStem Oncology, OxStem Neuro, OxStem Ocular and OxStem Cardio; aiming to treat cancer, Alzheimer's disease, age-related macular degeneration and heart failure respectively.
Contact: Michael Stein, Chairman and CEO; michael.stein@oxstem.co.uk; www.oxstem.co.uk

PDC*line Pharma, founded in 2014 as a spin-off of the French Blood Bank (EFS), is a Belgian-French biotech company that develops an innovative class of active immunotherapies for cancers, based on an allogeneic antigen presenting cell line (PDC*line). PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells. PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors. The technology can be applied for any type of cancer. Based on a first-in-human phase I study in melanoma, PDC*line Pharma focuses on the development of a clinical candidate for lung cancer. The company regroups a team of 13 peoples with a seasoned management team and raised more than 6M€ in equity and loans.

Contact: Eric HALIOUA, President & CEO; T**:** +32 474 05 78 66; e.halioua@pdc-line-pharma.com; www.pdc-line-pharma.com

PepVax, Inc. is an early-stage biotechnology company developing novel immunotherapy biologics to treat various cancers. Our proprietary development methodology along with the patented SMARTmid™ technology allows for a universal candidate that localizes the treatment for increased efficacy, decreased adverse effects, and decreased cost. Our focus is to develop immunotherapy that is more effective but also safer, affordable, and eventually curative.

Contact: Mahesh Narayanan, CEO; T: +1 856-343-2804; mahesh.narayanan@pepvax.co; www.pepvax.co

The Quebec Clinical Research Organization in Cancer (Q-CROC) is a consortium dedicated to the development, facilitation, and promotion of clinical research in oncology, as mandated by the Government of Quebec. Its mission is to maximize treatment options for cancer patients via participation in clinical trials. Acting as a bridge between the biopharmaceutical industry, governments, research communities, patient groups, and healthcare institutions, Q-CROC connects the right players. This in turn enhances clinical trial participation opportunities for patients, accelerates drug development, which enhances accessibility of anti-cancer treatments. Q-CROC's network currently includes 12 member institutions among the most active in clinical research in oncology in Quebec. A thirteenth institution is expected to join by the end of 2017.

Contact: Thérèse Gagnon Kugler, President & CEO; T: +1 418 781 0500, 102; tgagnon-kugler@qcroc.ca; www.qcroc.ca

Sareum is a specialist small molecule drug discovery and development company. The Company develops novel, targeted therapies for cancer and autoimmune disease, to licence to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage. Sareum operates an outsourced research model, working with international collaborators and a world-wide network of research providers. Its most advanced programme (Chk1) commenced clinical trials in May 2016 and was licensed to NASDAQ-listed Sierra Oncology in September 2016. Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR.

Contact: Tim Mitchell, CEO; T: +44 (0) 1223 497 703; Tim.Mitchell@sareum.co.uk; www.sareum.co.uk

Albert Wong, M.D. Group: We have developed technologies to improve a peptide vaccine to treat glioblastoma. EGFRvIII is an excellent target for precision medicine: a highly expressed, tumor specific alteration of the EGF receptor that is constitutively active and a marker for cancer stem cells. An anti-tumor peptide vaccine approach is an ideal off the shelf approach for treating glioblastoma. A randomized Phase II study for recurrent glioblastoma received Breakthrough Therapy Designation from the FDA. While a Phase III trial for newly diagnosed patients did not show superiority both control and vaccine arm significantly outperformed any previous study. Interestingly, the original peptide sequence was never optimized for an anti-tumor response. Using the crystal structure to guide our studies, we explored multiple sequence variations in animal tumor regression experiments and identified several candidates that significantly increased the survival rate over the original vaccine. These candidates also show an increase in several immunologic parameters. We are poised to begin work on a Phase I trial.

Contact: Albert Wong, MD Professor, Department of Neurosurgery and Cancer Biology Program, Stanford University Medical Center; T: +1 (650) 736-4220; ajwong@stanford.edu

SPARK at Stanford (Translational Medicine Program at Stanford School of Medicine): Overview of SPARK and Summary of SPARK Oncology assets available for licensing and potential start-ups.
Contact: Mahima Agochiya, PhD, MBA, Business Development and Program Manager at SPARK; T: +1 (925) 216 0203; Mahima.agochiya@stanford.edu

ZeClinics is a Contract Research Organization (CRO) and early-phase biopharmaceutical company (PHARMA) using zebrafish for drug discovery and biomedical research. We offer our services to Academia and Pharma; with potential extension to a wider range of industries: Cosmetic, Food, Wastewater, Chemical, and Agriculture. ZeClinics business strategy focuses on two activities. One, providing safety and efficacy assays and generating genetic models to third companies and academic groups (CRO area) and second, providing zebrafish-based drug discovery pipelines in Cardiovascular and Oncology therapeutic areas (Pharma area).
Contact: Dr. Javier Terriente Félix; CSO; T: +34 933 160 908; javier.terriente@zeclinics.com; www.zeclinics.com

Organizing Partners International Cancer Cluster Showcase 2017

Massachusetts Technology Transfer Center - Massachusetts' unique ecosystem of leading research institutions, supporting organizations, and investor community spurs the creation of numerous new companies every year. Massachusetts' cancer expertise is maintained by cutting edge research at multiple institutions including the Dana-Farber Cancer Institute and the David Koch Institute for Integrative Cancer Research at MIT. Many of the newly formed companies in the Commonwealth focus on cancer diagnostics and treatment. The Massachusetts Technology Transfer Center is a non-profit organization that supports technology transfer activities from public and private research institutions to companies in Massachusetts. To achieve this goal, the Center works with technology transfer offices at Massachusetts research institutions; faculty, researchers, and students who have commercially promising ideas; and companies across the Commonwealth.
Contacts: Abigail Barrow, abarrow@umassp.edu; Christa Bleyleben, cbleyleben@massglobalpartners.com; www.mttc.org

The Oncopole brings together various stakeholders to work on this structuring project. This partnership is a unique co-creation with an inclusive idea development and implementation process which involved over 50 experts from the scientific community collaborating over the past year to identify its priorities. Recognizing the range of resources and infrastructures currently available as well as the strategic positioning of many researchers here in Québec, this project will strengthen, to the patient's benefit, the research and innovation ecosystem.
The Oncopole mobilizes the community around a shared vision:
to create a flagship hub in oncology, internationally recognized for its cohesiveness, effectiveness and avant-garde approach;
to enable the incubation and creation of companies that will capitalize on innovation;
to generate direct positive benefits for patients;
to position cancer care in Québec among the best in the world in terms of clinical outcome, patient experience and system efficiency.
Contact: Richard Cloutier, Richard.cloutier@reseaubio-innovation.com; www.oncopole.ca

The Wistar Institute is the nation's first independent institution devoted to medical research and training. The Wistar Institute has evolved from its beginnings as an anatomical teaching museum to its present-day status as an international leader in basic biomedical research. In 1972, The Wistar Institute was designated a National Cancer Institute Cancer Center in basic research, a distinction it holds to this day. Wistar discoveries have led to the development of vaccines for rabies, rubella, and rotavirus, the identification of genes associated with breast, lung, and prostate cancer, and the development of monoclonal antibodies and other significant research technologies and tools.
Contact: Heather Steinman, HSteinman@Wistar.org; www.wistar.org

Oslo Cancer Cluster is an oncology focused research and industry cluster. Organized as non-profit member organization Oslo Cancer Cluster is dedicated to accelerate the development of new cancer treatments. The 90 members represent the entire R&D value chain and include academic research institutes, university hospitals, biotechs, investors, and international Pharma companies. The cluster's growing pipeline comprises innovative therapeutics and diagnostics including novel cancer immunotherapies in preclinical and clinical development. Around 30 of the members are gathered in the Oslo Cancer Cluster Incubator, situated in the Oslo Cancer Cluster Innovation Park. We share the innovation park with Ullern Upper Secondary School, the Cancer Registry of Norway and Oslo University Hospital.
Contact: Jutta Heix, jh@oslocancercluster.no; www.oslocancercluster.no

OBN is the Membership organization supporting and bringing together the UK's emerging life sciences companies, corporate partners and investors. Our 360-plus Member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland benefiting from our networking, partnering, purchasing, advising and advocacy activities.
Contact: john.harris@obn.org.uk; www.obn.org.uk

The Stanford SPARK program was created nine years ago with the overarching goal of translating Stanford's biomedical research discoveries into therapeutics that will positively impact patient care and the health of our society. The SPARK Program is a partnership between Stanford University and volunteers from the local biotechnology, pharmaceutical, and health care investment industries. SPARK's mission is three-fold: first, to help academic investigators overcome the obstacles intrinsic to moving research discoveries from bench to bedside; second, to educate faculty, postdoctoral fellows, and graduate students regarding the translational research process so that development of promising new discoveries becomes second nature at our institution; third, to promote efficient, cost-effective, and innovative approaches to discovery and development. As a non-profit program, SPARK can give special consideration to development projects that are generally neglected by the for-profit sector, including those targeting diseases of children, rare (orphan) diseases, and diseases of the developing world.
Contact: Nancy Anne Federspiel, nfeder@stanford.edu; www.med.stanford.edu

Medicen is the competitiveness cluster of the Paris Region and one of Europe's largest cluster in Life Sciences and Healthcare. Founded in 2005, it offers a unique forum connecting all the key stakeholders: leading research institutes, innovative SMEs, hospitals, incubators, large companies and territorial authorities. Medicen goal is to increase the attractiveness of the Paris region, strengthen the international competitiveness of the health sector and develop the economic growth of its members in strategic markets through collaborative innovation. With 300 members and more than 200 innovative SMEs, Medicen is a unique gateway to innovate with Paris Region actors. Medicen is structured around 5 major technological areas:

- In vitro diagnostics
- Diagnostic and interventional imaging systems
- Regenerative Medicine and biomaterials
- ICT for Health
- Translational medicine

Contact: Olivier Fontaine, ofontaine@medicen.org; www.medicen.org

Biocat acts as a strategic agent and catalyst in the construction of the Catalan healthcare and life sciences ecosystem. Its mission is to establish liasons between all the stakeholders of the BioRegion (companies, research groups and entities, hospitals and innovation support structures) to transform knowledge and technology into economic growth and to create a social impact. Biocat was created in 2006 at the behest of the Government of Catalonia and the Barcelona City Council to provide a joint strategy for the Catalan biosciences sector as the foundation of a new economy based on knowledge and innovation. www.biocat.cat/en

ACCIÓ (Catalonia Trade & Investment) is the Agency for Business Competitiveness in Catalonia. ACCIÓ connects businesses to the key strategic sectors, promotes internationalization and innovation, helps Catalan business and startups boost their competitiveness and helps international companies connect and tap into the competitive advantages Catalonia and Barcelona provide. ACCIÓ also works to attract foreign direct investment to Barcelona and Catalonia, promoting the area as an attractive, innovative and competitive business location. With headquarters in Barcelona, Catalonia Trade&Investment also operates from 36 offices around the world. www.catalonia.com
Contact: Marc Gràcia, marc.gracia@catalonia.com

POSTER PARTNER: Created in 2006, **BioWin** is the Health Cluster of Wallonia (Belgium) and its mission is to support the growth and competitiveness of the sector by bringing together stakeholders participating in R&D innovative projects and/or skills development in the fields of health biotechnology and medical technologies.

BioWin brings together more than 180 members who are active in the following key technological areas:

- Biopharmacy & Vaccines
- Cell therapy & Regenerative medicine
- Biomanufacturing 4.0
- Radiation Applications in healthcare.
- Digital Health
- Diagnostics (in vitro & in vivo)
- Implanted & Non-Implanted Medical devices

Special thanks to the ICCS2017 Sponsors:

Notes: